The Process Development Blog

[WEBINAR] Scale-up of crystallization processes is rarely trivial & often necessitates careful consideration and in-depth understanding of process parameters.

APC's Medicine Accelerator combines a €25M investment, iAchieve® digital platform, and 200+ scientists to accelerate CMC development and regulatory submissions.

APC unveils €25m investment and 120 jobs to accelerate development and manufacture of Covid Vaccines and Advanced Therapeutics.

Computational solvent screening narrows 70 candidates to under 10 in 2–3 days, with solubility predictions within 20% of experiment—applied to API crystal morphology design.

Combining laser light scattering and microscopy for pharmaceutical particle size analysis eliminates common measurement artefacts and provides verifiable, morphology-aware results.

On-demand webinar on drug substance development bottlenecks-solubility, particle size, and morphology-featuring computational screening strategies, presented by APC's Dr Jacek Zeglinski.

Industry Veteran Brett Huff has joined APC to head up our First-in-Class Digital Strategy for process development.

Subtle changes in particle size, shape, & distribution can have a major impact on pharma solubility and stability and cause flow and formulation issues.

APC marks Rare Disease Day, highlighting that only 5% of 7,000 known rare diseases have treatments, underscoring the urgency of pharma process development.

[WEBINAR] Good crystallization process design, can save months of development time. But, crystallization of stereoisomers can be particularly challenging.